Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery

Launched by MARIA CECILIA HOSPITAL · Jun 6, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the role of tiny particles called blood microvesicles and exosomes in patients who have undergone coronary artery bypass graft (CABG) surgery. CABG is a common procedure used to improve blood flow in patients with severe heart disease. The researchers want to understand how these particles may affect the success of the grafts used during surgery, as issues with graft function can lead to problems in the long run. The goal is to find ways to improve patient outcomes after surgery.

To participate in this trial, candidates must be between the ages of 40 and 80, have a heart function that is adequate (with an ejection fraction greater than 30%), and have undergone CABG surgery. Participants need to be willing to provide informed consent and attend follow-up visits as required. Those who have had emergency surgeries, changes in liver or kidney function, or other specific medical conditions may not be eligible. If you decide to take part, you can expect to contribute to important research that could help improve recovery and long-term success for patients undergoing heart surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • between the ages of 40 and 80
• • Ejection fraction\> 30%
• • coronary artery bypass surgery
• • informed consent
• • Willingness to carry out the follow-up visits and the assessments required by the protocol
• Exclusion Criteria:
• • emergency intervention
• • changes in liver or kidney function
• • changes in coagulation factors
• • associated interventions (valve replacement, carotid endarterectomy)